Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Jun 1, 2020 • 4:53 PM EDT
Ligand CEO Issues Letter to Captisol Customers
May 29, 2020 • 8:00 AM EDT
Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
May 28, 2020 • 4:22 PM EDT
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
May 6, 2020 • 1:30pm PDT
See all events
Mar 16, 2020 • 1:30pm EDT
Dana Point, CA
Mar 10, 2020 • 2:35pm EDT
Miami Beach, FL
Jun 10, 2020 • 8:30am PDT